東栄新薬 List of News Articles

Toei Shinyaku Co., Ltd. conducted a satisfaction survey among veterinarians regarding the outdoor-cultivated Agaricus (KA21 strain). [About the Survey] Test Product: A 300mg granule supplement made from outdoor-cultivated Agaricus (KA21 strain) from Brazil, without any additives. Survey Details: The product was orally administered at a rate of one granule per day for one month to 94 dogs and cats weighing 5-6 kg, and the satisfaction of veterinarians was investigated. Target Veterinarians: 44 facilities with 44 participants Survey Method: Internet survey conducted by Betpia from June to July 2021 [Results] The administration of outdoor-cultivated Agaricus (KA21 strain) confirmed a very high satisfaction rate among veterinarians, ranging from 80.6% to 93.1%.* *The satisfaction levels were categorized as very satisfied, satisfied, or dissatisfied, with values above "satisfied" being reported. **Part of the results from this survey was presented at the 25th Annual Conference of the Japanese Society of Veterinary Dermatology (March 27, 2022, Venue: International Fashion Center Building) in collaboration with the Faculty of Veterinary Medicine at Azabu University and the Department of Immunology at Tokyo University of Pharmacy and Life Sciences.

Tōei Shinyaku has obtained a patent for the measurement method of the main component β-glucan in Agaricus ~ Useful for diagnosing fungal diseases and measuring β-glucan content in supplements ~ Tōei Shinyaku Co., Ltd. (located in Mitaka City, Tokyo, CEO: Akira Motoi) has established a measurement method for β-glucan, the main component of Agaricus, as a result of research conducted in collaboration with the Department of Immunology at Tokyo University of Pharmacy and Life Sciences, focusing on our field-cultivated Agaricus KA21 strain (hereinafter referred to as Agaricus KA21). We are pleased to announce that this research outcome has been registered as a patent under the title "Measurement Method for β-1,6-Glucanase Mutant and β-1,6-Glucan."